11 completed. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 11 |
| Phase 2 | 2 | Completed 2 |
Follow Hemodialysis: new trials by email Literature Review of Hemodialysis trials Research Report on Hemodialysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Bee Venom on T Regulatory Cells and Inflammation in Hemodialysis Patients: a Prospective Study Thesis Bee Venom (BV) - Hemodialysis, Inflammation | Phase 1 / Phase 2 | Completed | Mansoura University | 60 | 2024-06-01 | 2026-10-30 |
| Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD Empagliflozin, Placebo - End-stage Kidney Disease, Kidney Disease, Chronic | Phase 1 | Completed | University of Utah | 62 | 2023-03-21 | 2026-10-30 |
| Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis INCB000928 - Renal Impairment, Hemodialysis | Phase 1 | Completed | Incyte Corporation | 48 | 2021-12-14 | 2023-05-15 |
| Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis. HEC53856 - Hemodialysis, Peritoneal Dialysis | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 60 | 2021-09-10 | 2025-05-15 |
| CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients CR845 0.5 mcg/kg, Placebo - Hemodialysis | Phase 1 | Completed | Cara Therapeutics, Inc. | 35 | 2019-12-31 | 2022-09-08 |
| Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects [14C] CR845 - Hemodialysis, Healthy | Phase 1 | Completed | Cara Therapeutics, Inc. | 12 | 2019-01-17 | 2019-07-24 |
| ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis roxadustat - Anemia, Hemodialysis | Phase 1 | Completed | Astellas Pharma Inc | 12 | 2010-02-15 | 2024-10-30 |
| Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis N-acetylcysteine, placebo - End-Stage Renal Disease, Dialysis | Phase 1 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 30 | 2007-03-01 | 2010-03-03 |
| Use of a Lifeline Graft in the A-V Shunt Model Lifeline - ESRD, Hemodialysis | Phase 1 / Phase 2 | Completed | Cytograft Tissue Engineering | 2004-09-01 | 2013-07-17 | |
| Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease CP-690,550 - End-Stage Renal Disease, Hemodialysis | Phase 1 | Completed | Pfizer | 12 | 2003-02-01 | 2012-12-18 |
| A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008) MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days - Renal Insufficiency, Hemodialysis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2003-01-01 | 2015-08-19 |
Kidney Failure, Chronic (7) · Renal Insufficiency (4) · Renal Insufficiency, Chronic (3) · Anemia (1) · Inflammation (1) · Lymphoma, Follicular (1) · Myositis Ossificans (1)
Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Kidney Diseases (9) · Male Urogenital Diseases (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Chronic Disease (8) · Disease Attributes (8) · Renal Insufficiency (5) · Renal Insufficiency, Chronic (5) · Hemic and Lymphatic Diseases (2) · Hematologic Diseases (1) · Immune System Diseases (1)
Acetylcysteine (1) · Bee Venoms (1) · Blood Vessel Prosthesis (1) · Duration of Therapy (1) · Sitagliptin Phosphate (1) · difelikefalin (1) · empagliflozin (1) · roxadustat (1) · tofacitinib (1)
Cara Therapeutics, Inc. (2) · Astellas Pharma Inc (1) · Cytograft Tissue Engineering (1) · Incyte Corporation (1) · Mansoura University (1) · Merck Sharp & Dohme LLC (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Pfizer (1) · Sunshine Lake Pharma Co., Ltd. (1) · University of Utah (1)
United States (6) · Argentina (1) · China (1) · Egypt (1) · Japan (1) · Poland (1)
Kirsten L Johansen, MD (1) · Lech Cierpka, MD PhD (1)
PMID 17468348, PMID 24030917, PMID 37369955, PMID 37651553, PMID 37916745
R01DK131265 (1), R21DK077350 (1), R44HL064462 (1)